Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


2 Aging (Albany NY)
1 Am J Cancer Res
1 Am J Transl Res
1 Br J Clin Pharmacol
1 Can J Urol
1 Cancer Biother Radiopharm
1 Cancer Causes Control
1 Cancer Sci
1 Cancers (Basel)
1 Cell Death Dis
1 Cells
1 Cureus
1 Eur J Clin Nutr
1 Gulf J Oncolog
2 Hum Pathol
1 Int J Gen Med
1 Int J Mol Sci
1 Int J Radiat Oncol Biol Phys
1 Int J Surg
2 Int J Urol
3 Int Urol Nephrol
1 Intractable Rare Dis Res
1 J Biomed Mater Res B Appl Biomater
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Coll Physicians Surg Pak
5 J Endourol
1 J Med Vasc
1 J Pediatr Surg
1 J Urol
1 J Vet Med Sci
1 Med J Islam Repub Iran
1 Mol Cell Biochem
1 Oncologist
1 Pathol Oncol Res
1 Pract Radiat Oncol
1 Precis Clin Med
1 Prostate Cancer Prostatic Dis
1 Spectrochim Acta A Mol Biomol Spectrosc
2 Transl Androl Urol
3 Urol J
7 Urol Oncol
1 Urology
1 World J Surg Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Aging (Albany NY)

  1. ZHAO W, Sun F, Zhang L, Ouyang J, et al
    NEAT1 variant 1 weakens the genome-wide effect of miR-3122 on blocking H3K79me3 in bladder cancer.
    Aging (Albany NY). 2022;14.
    PubMed         Abstract available

  2. YAO J, Qian K, Chen C, Liu X, et al
    Correction for: ZNF139/circZNF139 promotes cell proliferation, migration and invasion via activation of PI3K/AKT pathway in bladder cancer.
    Aging (Albany NY). 2022;undefined.

    Am J Cancer Res

  3. PARK J, Kamerer RL, Marjanovic M, Sorrells JE, et al
    Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.
    Am J Cancer Res. 2022;12:2068-2083.
    PubMed         Abstract available

    Am J Transl Res

  4. SONG P, Lu N, Zhang J, Gao X, et al
    Cause of death of patients with non-muscular invasive, non-metastatic muscular invasive and metastatic bladder cancer after diagnosis.
    Am J Transl Res. 2022;14:3494-3515.
    PubMed         Abstract available

    Br J Clin Pharmacol

  5. DE WIT R, Powles T, Castellano D, Necchi A, et al
    Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
    Br J Clin Pharmacol. 2022;88:3182-3192.
    PubMed         Abstract available

    Can J Urol

  6. PRUNTY M, Bukavina L, Mahran A, Mishra K, et al
    Risk factors for postoperative Clostridium difficile infection after radical cystectomy for bladder cancer: a NSQIP database analysis.
    Can J Urol. 2022;29:11170-11174.
    PubMed         Abstract available

    Cancer Biother Radiopharm

  7. WANG SS, Zhai GQ, Chen G, Huang ZG, et al
    Metadherin Promotes the Development of Bladder Cancer by Enhancing Cell Division.
    Cancer Biother Radiopharm. 2022 Jun 14. doi: 10.1089/cbr.2021.0392.
    PubMed         Abstract available

    Cancer Causes Control

  8. FREUDENBURG E, Bagheri I, Srinivas S, Martinez A, et al
    Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review.
    Cancer Causes Control. 2022 Jun 14. pii: 10.1007/s10552-022-01593.
    PubMed         Abstract available

    Cancer Sci

  9. TANG H, Li X, Jiang L, Liu Z, et al
    RITA1 drives the growth of bladder cancer cells by recruiting TRIM25 to facilitate the proteasomal degradation of RBPJ.
    Cancer Sci. 2022 Jun 14. doi: 10.1111/cas.15459.
    PubMed         Abstract available

    Cancers (Basel)

  10. LOKESHWAR SD, Lopez M, Sarcan S, Aguilar K, et al
    Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

    Cell Death Dis

  11. LU B, Wei J, Zhou H, Chen J, et al
    Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3.
    Cell Death Dis. 2022;13:547.
    PubMed         Abstract available


  12. STAKHOVSKYI O, Kobyliak N, Voylenko O, Stakhovskyi E, et al
    Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.
    Cells. 2022;11.
    PubMed         Abstract available


  13. ZHONG W, Qu H, Yao B, Wang D, et al
    Analysis of a Long Non-coding RNA associated Signature to Predict Survival in Patients with Bladder Cancer.
    Cureus. 2022;14:e24818.
    PubMed         Abstract available

    Eur J Clin Nutr

  14. PENG L, Meng C, Li J, You C, et al
    The prognostic significance of controlling nutritional status (CONUT) score for surgically treated renal cell cancer and upper urinary tract urothelial cancer: a systematic review and meta-analysis.
    Eur J Clin Nutr. 2021 Nov 23. pii: 10.1038/s41430-021-01014.
    PubMed         Abstract available

    Gulf J Oncolog

  15. IBRAHIM A, Khalid R, Mohager S, Fadl-Elmula I, et al
    Clinical Characteristics of Urinary Bladder Cancer in the Sudan; Evidence of Pathoetiology Changes.
    Gulf J Oncolog. 2022;1:16-20.
    PubMed         Abstract available

    Hum Pathol

  16. CHENG L, Zhang S, Wang M, Lopez-Beltran A, et al
    Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Hum Pathol. 2022 Jun 11. pii: S0046-8177(22)00150.
    PubMed         Abstract available

  17. WU D, Lee CT, Zynger DL
    Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival.
    Hum Pathol. 2022;125:79-86.
    PubMed         Abstract available

    Int J Gen Med

  18. CHEN R, Hu B, Jiang M, Deng W, et al
    Bioinformatic Analysis of the Expression and Clinical Significance of the DNA Replication Regulator MCM Complex in Bladder Cancer.
    Int J Gen Med. 2022;15:5465-5485.
    PubMed         Abstract available

    Int J Mol Sci

  19. WEI Y, Amend B, Todenhofer T, Lipke N, et al
    Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  20. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment.
    Int J Radiat Oncol Biol Phys. 2022 Jun 9. pii: S0360-3016(22)00598.
    PubMed         Abstract available

    Int J Surg

  21. ZHENG Y, Ye Y, Chen J, Wei Z, et al
    Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
    Int J Surg. 2022;103:106693.
    PubMed         Abstract available

    Int J Urol

  22. TAOKA R, Sugimoto M
    Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 11. doi: 10.1111/iju.14954.

    Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 9. doi: 10.1111/iju.14955.

    Int Urol Nephrol

  24. HE W, Yang J, Gao M, Liu H, et al
    Pelvic reconstruction and lateral prostate capsule sparing techniques improve early continence of robot-assisted radical cystectomy with orthotopic ileal neobladder.
    Int Urol Nephrol. 2022;54:1537-1543.
    PubMed         Abstract available

  25. BASOURAKOS SP, Al Hussein Al Awamlh B, Borregales LD, Abrahimi P, et al
    A comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy.
    Int Urol Nephrol. 2022;54:1513-1519.
    PubMed         Abstract available

  26. ZHU J, Lu Z, Ke M, Cai X, et al
    Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
    Int Urol Nephrol. 2022;54:1505-1512.
    PubMed         Abstract available

    Intractable Rare Dis Res

  27. MOUSSA M, Chakra MA, Duquesne I
    Intravesical MgSO4 for the treatment of BCG refractory T1 G3 bladder cancer: Preliminary results on efficacy and safety.
    Intractable Rare Dis Res. 2022;11:81-83.
    PubMed         Abstract available

    J Biomed Mater Res B Appl Biomater

  28. SHANMUGAM BK, Rangaraj S, Subramani K, Srinivasan S, et al
    Biomimetic development of chitosan and sodium alginate-based nanocomposites contains zirconia for tissue engineering applications.
    J Biomed Mater Res B Appl Biomater. 2022;110:1942-1955.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  29. KAJTEZOVIC S, Walker AR, Hjalmarsson B, Bell SG, et al
    Management of secondary Paget's disease of the vulva associated with transitional cell carcinoma.
    J Cancer Res Clin Oncol. 2022;148:1697-1702.
    PubMed         Abstract available

    J Clin Oncol

  30. ZENG S, Zhang Z, Xu C
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
    J Clin Oncol. 2022 Jun 15:JCO2200669. doi: 10.1200/JCO.22.00669.

    J Coll Physicians Surg Pak

  31. SENEL C, Asfuroglu A, Aykanat IC, Balci M, et al
    Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C.
    J Coll Physicians Surg Pak. 2022;32:768-772.
    PubMed         Abstract available

    J Endourol

  32. PATHAK RA, Hemal AK
    Editorial Comment on: "Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group)" by Veccia et al.
    J Endourol. 2022;36:760-761.

  33. MOROZOV A, Babaevskaya D, Taratkin M, Inoyatov J, et al
    Systematic Review: The Learning Curve for Robot-Assisted Radical Cystectomy-What Do We Know?
    J Endourol. 2022;36:770-784.
    PubMed         Abstract available

  34. ALBISINNI S, Diamand R, Mjaess G, Aoun F, et al
    Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.
    J Endourol. 2022;36:785-792.
    PubMed         Abstract available

  35. VECCIA A, Carbonara U, Djaladat H, Mehazin R, et al
    Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group).
    J Endourol. 2022;36:752-759.
    PubMed         Abstract available

  36. MUTAGUCHI J, Morooka K, Kobayashi S, Umehara A, et al
    Artificial Intelligence for Segmentation of Bladder Tumor Cystoscopic Images Performed by U-Net with Dilated Convolution.
    J Endourol. 2022;36:827-834.
    PubMed         Abstract available

    J Med Vasc

  37. PALMIER M, Monnot A, Teniere T, Cohen Q, et al
    Mycotic arterial aneurysm secondary to BCG intravesical instillation: A review.
    J Med Vasc. 2022;47:94-105.
    PubMed         Abstract available

    J Pediatr Surg

  38. ELSHARNOBY O, Fraser N, Williams A, Scriven S, et al
    Bladder urothelial cell carcinoma as a rare cause of haematuria in children: Our experience and review of current literature.
    J Pediatr Surg. 2022;57:1409-1413.
    PubMed         Abstract available

    J Urol

  39. SONG Y, Du Y, Qin C, Bai F, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Letter.
    J Urol. 2022;208:222-223.

    J Vet Med Sci

  40. PARK J, Nam A, Lee HB, Jeong SM, et al
    Leiomyosarcoma of urinary bladder in a Shih Tzu dog.
    J Vet Med Sci. 2022;84:799-803.
    PubMed         Abstract available

    Med J Islam Repub Iran

  41. ARIAFAR A, Zeighami S, Salehipour M, Ahmed F, et al
    An Investigation of the Pathology Report of Bladder Cancer Patients with Radical Cystectomy in Southern Iran, 2013-2018: A Cross-Sectional Study.
    Med J Islam Repub Iran. 2021;35.
    PubMed         Abstract available

    Mol Cell Biochem

  42. CHEN MC, Annseles Rajula S, Bharath Kumar V, Hsu CH, et al
    Tannic acid attenuate AKT phosphorylation to inhibit UMUC3 bladder cancer cell proliferation.
    Mol Cell Biochem. 2022 Jun 13. pii: 10.1007/s11010-022-04454.
    PubMed         Abstract available


  43. JUN T, Hahn NM, Sonpavde G, Albany C, et al
    Phase II Clinical and Translational Study of Everolimus +/- Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
    Oncologist. 2022;27:432-e452.
    PubMed         Abstract available

    Pathol Oncol Res

  44. YANG Y, Yu J, Xiong Y, Xiao J, et al
    Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer.
    Pathol Oncol Res. 2022;28:1610267.
    PubMed         Abstract available

    Pract Radiat Oncol

  45. VERGHOTE F, Sargos P, Christodouleas JP, Murthy V, et al
    International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup.
    Pract Radiat Oncol. 2022 Jun 9. pii: S1879-8500(22)00190.
    PubMed         Abstract available

    Precis Clin Med

  46. DENG L, Jin K, Zhou X, Zhang Z, et al
    Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells.
    Precis Clin Med. 2022;5:pbac007.
    PubMed         Abstract available

    Prostate Cancer Prostatic Dis

  47. WELLIVER C, Feinstein L, Ward JB, Kirkali Z, et al
    Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Prostate Cancer Prostatic Dis. 2022;25:269-273.
    PubMed         Abstract available

    Spectrochim Acta A Mol Biomol Spectrosc

  48. ELAWADY T, Khedr A, El-Enany N, Belal F, et al
    Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor "Erdafitinib": Application to human plasma.
    Spectrochim Acta A Mol Biomol Spectrosc. 2022;278:121327.
    PubMed         Abstract available

    Transl Androl Urol

  49. TU J, Bao W, Ye X, Wu J, et al
    Laparoscopic radical cystectomy could be used in the clinical surgical treatment of bladder cancer patients.
    Transl Androl Urol. 2022;11:731-732.

  50. ZHU J, Lu Z, Chen W, Ke M, et al
    Systematic review and meta-analysis on laparoscopic cystectomy in bladder cancer: reply letter.
    Transl Androl Urol. 2022;11:733-734.

    Urol J

  51. ANSARI DJAFARI A, Javanmard B, Razzaghi M, Hojjati SA, et al
    Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Urol J. 2022 Jun 11. pii: 7194. doi: 10.22037/uj.v19i.7194.
    PubMed         Abstract available

  52. KADONO Y, Kawaguchi S, Nohara T, Shigehara K, et al
    Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST.
    Urol J. 2021;19:202-208.
    PubMed         Abstract available

  53. BAYAT AA, Sadeghi N, Salimi A, Fazli G, et al
    The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma.
    Urol J. 2021;19:189-195.
    PubMed         Abstract available

    Urol Oncol

  54. HURST CD, Knowles MA
    Mutational landscape of non-muscle-invasive bladder cancer.
    Urol Oncol. 2022;40:295-303.
    PubMed         Abstract available

  55. DA COSTA JB, Gibb EA, Nykopp TK, Mannas M, et al
    Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
    Urol Oncol. 2022;40:287-294.
    PubMed         Abstract available

  56. SANGUEDOLCE F, Meneghetti I, Bevilacqua G, Montano B, et al
    Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: When and which patients can benefit most from it?
    Urol Oncol. 2022;40:344.
    PubMed         Abstract available

  57. WILLIAMS SB, Shan Y, Fero KE, Movva G, et al
    Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:345.
    PubMed         Abstract available

  58. DAS JP, Woo S, Ghafoor S, Andrieu PIC, et al
    Value of MRI in evaluating urachal carcinoma: A single center retrospective study.
    Urol Oncol. 2022;40:345.
    PubMed         Abstract available

  59. UCHIMOTO T, Nakamura K, Komura K, Fukuokaya W, et al
    Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:344.
    PubMed         Abstract available

  60. FUKUOKAYA W, Kimura T, Komura K, Uchimoto T, et al
    Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
    Urol Oncol. 2022;40:346.
    PubMed         Abstract available


  61. INOUE T, Miyake M, Nishimura N, Onozawa M, et al
    Association of increased age with decreased response to intravesical instillation of Bacille Calmette-Guerin in patients with high-risk non-muscle invasive bladder cancer: Retrospective multi-institute results from the Japanese Urological Oncology Res
    Urology. 2022 Jun 11. pii: S0090-4295(22)00455.
    PubMed         Abstract available

    World J Surg Oncol

  62. MATSUZAWA N, Nishikawa T, Ohno R, Inoue M, et al
    Paraganglioma of the urinary bladder initially diagnosed as gastrointestinal stromal tumor requiring combined resection of the rectum: a case report.
    World J Surg Oncol. 2022;20:185.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.